Hospital de Câncer de Barretos-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2023

  1. Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis

    American Journal of Hematology

2022

  1. MM-188 Depth of Response of Isatuximab plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Updated Analysis

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S411-S412